RELEVANCE OF MOLECULAR TESTS FOR HTLV-1 INFECTION AS CONFIRMATORY TESTS AFTER THE FIRST SERO-SCREENING

The diagnosis of human T-cell leukemia virus type-1 (HTLV-1) infection has been widely examined by serologics. In the first screening tests, serological false negative and positive samples have been reduced thanks to advances in assay techniques that apply new emission agents and sensors. On the other hand, western blot (WB) remains problematic. For example, WB analysis yields many samples equivalent to antibody positive ones. To reduce the need for WB, an alternative testing strategy is required to detect HTLV-1 infection. Polymerase chain reaction (PCR) for the HTLV-1 provirus has recently been recommended for a final diagnosis of infection. However, although PCR is thought to be one element, the validation of detection performance for HTLV-1 infection between serological and molecular testing is not always clear. Thus, this study aimed to evaluate the accuracy and test the validity of an improved methodology for serological detection of HTLV-infection, as well as that of PCR. In conclusion, the high values of kappa-statistics are expected to deliver high quality in chemiluminescent enzyme immunoassay (or chemiluminescent immunoassay), while the problems with WB assays remain to be elucidated. As an alternative to WB, a combination of real-time qPCR and nested PCR is proposed as a suitable confirmatory test.

[1]  H. Rafatpanah,et al.  Design and development of a quantitative real time PCR assay for monitoring of HTLV-1 provirus in whole blood. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[2]  M. Satake,et al.  Intra‐ and inter‐laboratory variability in human T‐cell leukemia virus type‐1 proviral load quantification using real‐time polymerase chain reaction assays: A multi‐center study , 2010, Cancer science.

[3]  K. Yamaguchi,et al.  Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. , 2010, Blood.

[4]  K. Yamaguchi,et al.  Trends in HTLV‐1 prevalence and incidence of adult T‐cell leukemia/lymphoma in Nagasaki, Japan , 2010, Journal of medical virology.

[5]  E. Murphy,et al.  Quantitation of HTLV-I and II proviral load using real-time quantitative PCR with SYBR Green chemistry. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[6]  S. Kamihira,et al.  Significance of HTLV-1 proviral load quantification by real-time PCR as a surrogate marker for HTLV-1-infected cell count. , 2003, Clinical and laboratory haematology.

[7]  A. Lézin,et al.  Quantitation of HTLV-I proviral load by a TaqMan real-time PCR assay. , 2002, Journal of virological methods.

[8]  A. Lézin,et al.  Quantification of HTLV type I and HIV type I DNA load in coinfected patients: HIV type 1 infection does not alter HTLV type I proviral amount in the peripheral blood compartment. , 2001, AIDS research and human retroviruses.

[9]  M. Tomonaga,et al.  Real-time polymerase chain reaction for quantification of HTLV-1 proviral load: application for analyzing aberrant integration of the proviral DNA in adult T-cell leukemia. , 2000, International journal of hematology.

[10]  S. Katamine,et al.  Primary prevention of HTLV-1 in Japan. , 1997, Leukemia.

[11]  T. Takezaki,et al.  Inhibitory effect of maternal antibody on mother‐to‐child transmission of human T‐lymphotropic virus type I , 1991, International journal of cancer.

[12]  H. Miyakoshi,et al.  Improvement of Gelatin Particle Agglutination Test for Detection of Anti‐HTLV‐I Antibody , 1991, Japanese journal of cancer research : Gann.

[13]  T. Miyamoto,et al.  Prevention of mother-to-child transmission of human T-lymphotropic virus type-I. , 1990, Pediatrics.

[14]  C. Cossen,et al.  Comparison of immunofluorescence, enzyme immunoassay, and Western blot (immunoblot) methods for detection of antibody to human T-cell leukemia virus type I , 1988, Journal of clinical microbiology.

[15]  K. Kusuhara,et al.  Mother‐to‐child transmission of human T‐cell leukemia virus type I (HTLV‐1): A fifteen‐year follow‐up study in Okinawa, Japan , 1987, International journal of cancer.

[16]  Mitsuhiro Osame,et al.  HTLV-I ASSOCIATED MYELOPATHY, A NEW CLINICAL ENTITY , 1986, The Lancet.

[17]  M. Ichijo,et al.  Prevention of HTLV-I transmission through the breast milk by a freeze-thawing process. , 1986, Japanese journal of cancer research : Gann.

[18]  M. Yoshida,et al.  Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[19]  H. Taguchi,et al.  Enzyme-linked immunosorbent assay of antibodies to adult T-cell leukemia-associated antigens. , 1983, Gan.

[20]  M. Reitz,et al.  The virus of Japanese adult T-cell leukaemia is a member of the human T-cell leukaemia virus group , 1982, Nature.

[21]  M. Yoshida,et al.  Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[22]  K. Nagata,et al.  Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[23]  John D. Minna,et al.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma , 1980, Proceedings of the National Academy of Sciences.

[24]  K. Miyamoto,et al.  A novel T-cell line derived from adult T-cell leukemia. , 1980, Gan.

[25]  S. Katamine,et al.  Primary prevention of HTLV-I in Japan. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[26]  T. Fujiyoshi,et al.  Evaluation of commercial HTLV-1 test kits by a standard HTLV-1 serum panel. , 1995, Bulletin of the World Health Organization.

[27]  Acquired immunodeficiency syndrome (AIDS). Proposed WHO criteria for interpreting results from western blot assays for HIV-1, HIV-2, and HTLV-I/HTLV-II. , 1990, Releve epidemiologique hebdomadaire.

[28]  S. Yashiki,et al.  HLA haplotype‐linked high immune responsiveness against HTLV‐I in HTLV‐I‐associated myelopathy: Comparison with adult T‐cell leukemia/lymphoma , 1988, Annals of neurology.